Passage BIO, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended | ||||||
| · · December 31, | ||||||
| (in thousands) · · 2025 · · 2024 | ||||||
| Cash flows used in operating activities: · · · · | ||||||
| Net loss | | $(45,522) | | $(64,767) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | | | | ||
| Depreciation and amortization | | 728 | | 3,081 | ||
| Share‑based compensation | | 3,001 | | 5,820 | ||
| Amortization of premium and discount on marketable securities, net | | | 129 | | | (1,527) |
| Impairment of long-lived assets | | | 6,145 | | 5,233 | |
| Other non-cash items | | 14 | | — | ||
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets, and other assets | | 228 | | 255 | ||
| Prepaid research and development | | 391 | | 1,521 | ||
| Non-refundable sublicense and transition services payments received | | | 4,015 | | | 8,226 |
| Right of use assets and operating lease liabilities | | | (464) | | | (279) |
| Accounts payable | | 1,880 | | (556) | ||
| Accrued expenses and other current liabilities | | (2,054) | | (4,963) | ||
| Net cash provided by (used in) operating activities | | (31,509) | | (47,956) | ||
| Cash flows provided by (used in) investing activities: | | | | | ||
| Purchases of marketable securities | | — | | (88,170) | ||
| Sales or maturities of marketable securities | | 39,046 | | 143,150 | ||
| Purchases of property and equipment and other assets | | — | | (34) | ||
| Sales of property and equipment and other assets | | 1,170 | | — | ||
| Net cash provided by (used in) investing activities | | 40,216 | | 54,946 | ||
| Cash flows provided by (used in) financing activities: | | | | | ||
| Proceeds from issuance of common stock under the ATM Facility, net of offering costs | | | — | | | 8,742 |
| Proceeds from the exercise of stock options | | — | | 35 | ||
| Proceeds from the issuance of common stock under employee stock purchase plan | | | 23 | | | 97 |
| Net cash provided by (used in) financing activities | | 23 | | 8,874 | ||
| Net increase (decrease) in cash and cash equivalents | | 8,730 | | 15,864 | ||
| Cash and cash equivalents at beginning of year | | 37,573 | | 21,709 | ||
| Cash and cash equivalents at end of year | | $46,303 | | $37,573 | ||
| Supplemental disclosure of non‑cash activities: | | | | | ||
| Unrealized gain (loss) on marketable securities | | $(8) | | $51 | ||
| Right of use assets recognized upon the commencement of sublease | | $— | | $(422) | ||
| Operating lease liabilities recognized upon the commencement of sublease | | $— | | $422 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.